Michał Nowicki

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 612 citations · Full text

Medicine, Endocrinology, Nephrology +10

Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe — recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency

Paweł Płudowski, Elżbieta Karczmarewicz, Milan Bayer et al. · Endokrynologia Polska · 2013 · 521 citations · Full text

Agriculture, Nutrition, Nutritional Sciences +17

Reduced Urinary Excretion of Nitric Oxide Metabolites and Increased Plasma Levels of Asymmetric Dimethylarginine in Men with Essential Hypertension

Andrzej Surdacki, Michał Nowicki, Joerg Sandmann et al. · Journal of Cardiovascular Pharmacology · 1999 · 429 citations

Medicine, Endocrinology, Pharmacology +13

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

Hiddo J.L. Heerspink, Bergur V. Stefánsson, Glenn M. Chertow et al. · Nephrology Dialysis Transplantation · 2019 · 216 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17